Drug Profile
Rhenium (186Re) obisbemeda - Plus Therapeutics
Alternative Names: 186-Rheneium nanoliposome-Plus Therapeutics; 186RNL; Re-186; Rhenium-186 NanoLiposome; RNL™Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator Plus Therapeutics
- Class Antineoplastics; Heavy metals; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioma
- Phase I/II Meningeal carcinomatosis
- Preclinical Brain cancer; Peritoneal cancer; Squamous cell cancer
Most Recent Events
- 22 Apr 2024 Plus Therapeutics plans a phase I trial for Brain cancer (In children, In infants, In neonates) in the second half of 2024
- 11 Mar 2024 Updated adverse events data from the phase I ReSPECT-LM trial in Meningeal carcinomatosis released by Plus Therapeutics
- 05 Mar 2024 Plus Therapeutics plans to meet US FDA to align on the design for a pivotal Phase II/III ReSPECT-LM trial for the treatment of breast cancer with leptomeningeal metastases